Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for argenex SE (ARGX : NSDQ)

• Company Description    argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. Number of Employees: 1,599

• Price / Volume Information    Yesterday's Closing Price: $546.04 Daily Weekly Monthly 20 Day Moving Average: 384,826 shares Shares Outstanding: 61.06 (millions) Market Capitalization: $33,340.96 (millions) Beta: 0.37 52 Week High: $678.21 52 Week Low: $432.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.44% -9.80% 12 Week -9.95% -21.86% Year To Date -11.21% -16.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL LAARDERHOOGTWEG 25 - AMSTERDAM,P7 1101EB NLD ph: 31-10-703-8441 fax: - aroy@argenx.com http://www.argenx.com

• General Corporate Information    Officers Tim Van Hauwermeiren - Chief Executive Officer and Director Karen Massey - Chief Operating Officer Karl Gubitz - Chief Financial Officer Arjen Lemmen - Vice-President Corporate Development & Strategy Werner Lanthaler - Director Peer Information argenex SE (CORR.) argenex SE (RSPI) argenex SE (CGXP) argenex SE (BGEN) argenex SE (GTBP) argenex SE (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04016X101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/24/25 Share - Related Items Shares Outstanding: 61.06 Most Recent Split Date: (:1) Beta: 0.37 Market Capitalization: $33,340.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $3.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $12.79 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 43.23% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/24/25

• Fundamental Ratios P/E Current FY Estimate: 42.68 Trailing 12 Months: 91.01 PEG Ratio: 0.99 Price Ratios Price/Book: 6.03 Price/Cash Flow: 183.82 Price / Sales: 12.60 EPS Growth vs. Year Ago Period: 348.08% vs. Previous Quarter: 63.29% Sales Growth vs. Year Ago Period: 95.72% vs. Previous Quarter: 6.06% ROE 06/30/25 - - 03/31/25 - 16.15 12/31/24 - 6.68 ROA 06/30/25 - - 03/31/25 - 14.33 12/31/24 - 5.93 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 7.29 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 6.68 Operating Margin 06/30/25 - - 03/31/25 - 14.89 12/31/24 - 7.24 Net Margin 06/30/25 - - 03/31/25 - 40.20 12/31/24 - 36.99 Pre-Tax Margin 06/30/25 - - 03/31/25 - 13.67 12/31/24 - 3.78 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 90.49 Inventory Turnover 06/30/25 - - 03/31/25 - 1.44 12/31/24 - 1.24 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©